Mr. Bakema has a forty year track record of successfully creating and developing businesses from the ground up. He has overseen multiple organizations with a human resource development of several hundred employees and contractors. His extensive background in business management, capitalization, mergers and acquisitions has been combined with years of hands on leadership experience in the medical device arena. This has given him the ability to adapt quickly to an ever changing healthcare sector. As the Chairman and CEO of CVR Global for the last ten years, Mr. Bakema is responsible for the direction of CVR Global with an emphasis on a sound business infrastructure that is capable of rapid scalability and regulatory compliance.
Tony RobinsonChief Operations Officer & Executive Vice President
Mr. Robinson is a passionate leader, seasoned by guiding multiple organizations within the medical device field. His experience encompasses management of operational, marketing, regulatory, and financial areas on domestic and global stages, with a specialization in successfully meeting both regulatory and business needs. He has earned a degree from the University of Michigan, as well as an MBA in Healthcare Management. Mr. Robinson has been immersed in the day to day workings of CVR Global Inc. over the past eight years, driving progress and growth across all key clinical and operational functions, with a focus on both the end user acceptance and market commercialization. Previously, Mr. Robinson was responsible for the management of regulatory actives for a recognized global medical device manufacturer, placing over 25,000 SKU’s into the healthcare marketplace. This was preceded by a role with a top tiered clinical care organization as Director of Marketing.
Tom HarrisCFO & Executive Vice President
Over a career spanning nearly 50 years, Mr. Harris has held various senior executive roles within both public and non-public companies, including Time Warner, Inc., the Associated Press, and several development stage and start-up entities within the biotech and medical device industries. Mr. Harris played a key role in the successful Initial Public Offering of American Television and Communications Corporation, predecessor to Time Warner Cable (TWC), as well as leading the effort to decentralize the TWC’s operations into several dozen autonomous operating units. While serving as CFO of TWC, Mr. Harris lead the efforts to structure, finance and complete several multi-billions dollar (and smaller) acquisitions, and successfully integrate the acquired businesses into TWC, and manage a financing and capital allocation process that resulted in $5 billion in capital investments to improve and increase TWC’s operating footprint.
Michael RhodesVice President of Quality Systems
Mr. Rhodes is a global senior leader with 20 years of quality and business transformation experience in high tech industries. Most recently as Chief Quality Officer and head of Learning Services at Motorola Solutions Inc. He has worked in multiple markets including healthcare, defense, public safety, retail, energy, and manufacturing and has a successful track record of developing agile quality management systems designed to support customer and business operations. Previous business transformation engagements in the US and Europe include Oracle, KPMG and Microsoft Consulting. Prior to his career in quality, Mr. Rhodes was in customer facing roles project managing sea-to-air data link systems for the Royal Navy, computer aided command and control for the British Ministry of Defense, and communication systems for Shell.
Marc LubowVice President Capital Markets & Director of Investor Relations
Mr. Lubow brings CVR valuable public market expertise, having over 25 years experience in business development, strategic alliances and partnerships, corporate communications, investor relations, investment banking, corporate finance, capital markets, transaction negotiation and execution. Mr. Lubow has a successful track record as a senior executive officer and consultant for both public and private sector companies. During his career, he has assisted with the completion of numerous public and private funding transactions, which totaled in excess of $800MM. He has worked in various capacities with numerous companies resulting in the successful completion of an aggregate of $1B in transactions. Mr. Lubow was formerly the Executive Vice President at Li3 Energy Inc. where he was responsible for all Strategic Development Projects, Licensing Agreements, Corporate Finance, Corporate and Investor Communications. Mr. Lubow is a decorated Veteran and Non-Commissioned Officer, Paratrooper, Air Traffic Controller of the US Army.
Ron BirchBoard Director
Mr. Birch has been President of Big Bar Resources Corporation, since November 2008 and served as its Chief Executive Officer until September 2016. Mr. Birch served as President and Chief Executive Officer of Okana Ventures Inc. from May 9, 2005 to June 2008. Mr. Birch has 17 years of experience with the Bank of Nova Scotia in various positions and locations throughout the Province of British Columbia, lastly as Branch Manager in Prince Rupert, B.C. He worked for 7 years as a retail stock broker with CM Oliver & Co., Ltd. and Pacific International Securities Inc. in Vancouver. During this time, Mr. Birch also took courses for Options and Commodities and was successful in completing these courses and obtaining certificates and licenses for each. Mr. Birch has been providing consulting services through Janron Consulting Inc. since 1991 and services of a Public Relations Coordinator through Bircress Corporate Relations since 1993. From 1985 to 1991, he was a licensed Stock, Commodities and Options Broker. He has been a Director of Big Bar Resources Corporation since November 14, 2008. Mr. Birch served as a Director of Okana Ventures Inc. from May 9, 2005 to June 2008 and Jupiter Enterprises Inc. since March 12, 1999.
Dallas HackBoard Director
Colonel Dallas Hack has led a decorated medical and military career. Prior to his service with the United States Army Medical Research and Materiel Command (USAMRMC), he developed a background in computer sciences and engineering, and served as Vice President for several biomedical companies. As a brain injury expert, he directed the Combat Casualty Care Research Program (CCCRP) at USAMRMC, where he was accountable for coordinating traumatic brain injury (TBI) research and technology across all Department of Defense groups. From 2008 to 2014, he oversaw projects that received over $2 billion in grant funding to advance TBI research and technology. His other appointments include Command Surgeon for the Multinational Force in Iraq and, up until his retirement in 2015, Senior Medical Advisor to the Principal Assistant, Research and Technology, USAMRMC.
Paul Blunden, M.D.Board Director & Medical Advisor
Dr. Blunden is a board certified physician in obstetrics and gynecology with over twenty years in practice. Currently acting as the vice president and partner of a large multi-million dollar multi-provider practice servicing urban, suburban and rural patients. He has previously served as a department chairman for a major health system and has been a member of the executive leadership committee focused on fiscal management, quality improvement and recruiting. Mr. Blunden specializes in both Micro and Macro level managerial decision making with an emphasis on patient care and efficient business/medical coalescing.
Joel KanterBoard Director
Mr. Kanter has served as President of Windy City, Inc. a privately held investment firm since July 1986. He is a veteran healthcare venture capitalist whose family office has financially backed numerous medical device, life science and healthcare companies. Mr. Kanter has helped create billions in shareholder value, most notably; I-Flow which in 2009 was acquired by Kimberly-Clark for $324M, Clarisonic which in 2011 was acquired by L’Oréal for $525M, Prolor BioSciences which was acquired by OPKO Health in 2013 for USD $480M, Encore Medical which was acquired in 2006 by Blackstone for $860M, GranCare which in 1999 completed a $1.8B merger with Living Centers of America led by Apollo Management and Walnut Financial where he was Chief Executive Officer which was acquired in a transaction with Tower Hill Capital which resulted in an increase of $400M in shareholder value in 1999.Mr. Kanter currently serves on the Board of Directors of two public companies including Magna-Labs, Inc. and MEDITE Cancer Diagnostics, Inc. and also serves on the Boards of several private concerns. Mr. Kanter is also a Trustee Emeritus and past President of the Board of Trustees of The Langley School in McLean, Virginia, a former Trustee at the Georgetown Day School in Washington, D.C., and of the Union Institute & University.
Wayne HellmanVice Chairman & Board Director
Mr. Hellman’s career spans forty years having spent 16 years in various senior management roles with General Electric, culminating with the final four years reporting directly to Jack Welch (Chairman/CEO) where he led GE’s Venture Lighting Portfolio. In 1983, Mr. Hellman founded Advanced Lighting Technologies and served as its Chief Executive Officer until his retirement in 2014. Advanced Lighting Technologies, a Global Leader in Specialty Chemicals, Advanced Materials, Thin Film Coatings, Metal Halide Lighting and other Specialty Lighting Products launched with first year sales of $900,000. During his tenure, Mr. Hellman maintained consistent revenue growth and expanded global influence achieving Global revenue in excess of $250M. With manufacturing facilities and sales offices in 9 countries, employee headcount in excess of 1,000, completing 7 acquisitions and four international joint ventures in the Asian Pacific market, in 1995, Mr. Hellman led Advanced Lighting’s Initial Public Offering. In addition, he completed three secondary offerings totaling $200M, as well as completing a $100M high yield debt offering. Mr. Hellman took the Company Private in 2003 and prior to his retirement, in 2012 he led and completed an additional $170M High Yield Debt Offering where a significant amount was a distribution to the company’s shareholders.